SCHEMBL6182907

SCHEMBL6182907

COc1ccc(Oc2ccc(N)c(C)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
NR4A1 P22736 1/20 0.50
LTA4H P09960 2/20 0.48
ALDH1A1 P00352 7/20 0.47
CYP3A4 P08684 3/20 0.47
TDP1 Q9NUW8 3/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 1/20 0.45
PARP10 Q53GL7 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8762387 0.92 NR4A1 (0.58) SMN1; SMN2NR4A1ALDH1A1CYP3A4TDP1
SCHEMBL486670 0.89 NR4A1 (0.61) SMN1; SMN2NR4A1ALDH1A1CYP3A4TDP1
SCHEMBL29568160 0.87 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1CYP3A4TDP1MAPK1
SCHEMBL91981 0.87 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1CYP3A4TDP1MAPK1
SCHEMBL10350063 0.86 ALDH1A1 (0.61) SMN1; SMN2NR4A1ALDH1A1CYP3A4TDP1
SCHEMBL10353183 0.86 ALDH1A1 (0.58) SMN1; SMN2NR4A1LTA4HALDH1A1CYP3A4
SCHEMBL7185516 0.86 ALDH1A1 (0.61) SMN1; SMN2NR4A1ALDH1A1CYP3A4TDP1
SCHEMBL31457310 0.86 ALDH1A1 (0.61) SMN1; SMN2NR4A1ALDH1A1CYP3A4TDP1
Hydrochloric Acid SCHEMBL8946354 0.85 ALDH1A1 (0.63) SMN1; SMN2ALDH1A1CYP3A4TDP1MAPK1
Ammonia Solution, Strong SCHEMBL1854404 0.85 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1CYP3A4TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919332-B2 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-19 US disclosed
EP-1507535-A1 PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-23 EP disclosed
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-18 US disclosed
WO-2003090751-A1 PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 SMN1; SMN2 2876/4885NR4A1 652/4885LTA4H 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.